US2002123041A1PendingUtilityA1

Method for treatment of canine distemper

56
Priority: Dec 28, 1999Filed: Apr 30, 2002Published: Sep 5, 2002
Est. expiryDec 28, 2019(expired)· nominal 20-yr term from priority
Inventors:John Mcmichael
A61K 39/175C12N 2760/18434A61K 39/12A61P 31/12Y10S424/818A61K 2039/5254A61K 2039/552A61K 2039/70
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.

Claims

exact text as granted — not AI-modified
What is claimed:  
     
         1 . A method for treating a animal suffering from canine distemper comprising the step of: 
 administering a composition comprising an attenuated canine distemper virus at a sub-vaccine level effective to alleviate symptoms of canine distemper.    
     
     
         2 . The method of  claim 1  wherein said composition comprises from about 10 −3  TCID 50  to about 500 TCID 50  attenuated canine distemper virus per dose.  
     
     
         3 . The method of  claim 1  wherein said composition comprises about 2 TCID 50  attenuated canine distemper virus per dose.  
     
     
         4 . The method of  claim 1  wherein said composition is administered to a animal in a single dose of about 0.2 cc in a pharmaceutically acceptable carrier.  
     
     
         5 . The method of  claim 1  wherein multiple daily doses of said composition are administered to the animal.  
     
     
         6 . The method of  claim 1  where the composition is administered to a animal by a means selected from the group consisting of subcutaneously, intravenously and intramuscularly.  
     
     
         7 . The method of  claim 6  wherein the composition is administered to a animal subcutaneously.  
     
     
         8 . A composition for treatment of the symptoms of canine distemper comprising an attenuated canine distemper virus at a sub-vaccine level effective to alleviate symptoms of canine distemper in a pharmaceutically acceptable carrier.  
     
     
         9 . The composition of  claim 8  wherein from about 10 −3  TCID 50  to about 500 TCID 50  attenuated canine distemper virus per dose.  
     
     
         10 . The composition of  claim 9  which comprises 2 TCID 50  attenuated canine distemper virus per dose.  
     
     
         11 . A method for treating a animal suffering from canine distemper comprising the step of: 
 administering a composition comprising an attenuated canine measles virus at a sub-vaccine level effective to alleviate symptoms of canine distemper.    
     
     
         12 . The method of  claim 11  wherein said composition comprises from about 10 −3  TCID 50  to about 500 TCID 50  attenuated canine measles virus per dose.  
     
     
         13 . The method of  claim 11  wherein said composition comprises about 2 TCID 50  attenuated canine measles virus per dose.  
     
     
         14 . The method of  claim 11  wherein said composition is administered to a animal in a single dose of about 0.2 cc in a pharmaceutically acceptable carrier.  
     
     
         15 . The method of  claim 11  wherein multiple daily doses of said composition are administered to the animal.  
     
     
         16 . The method of  claim 11  where the composition is administered to a animal by a means selected from the group consisting of subcutaneously, intravenously and intramuscularly.  
     
     
         17 . The method of  claim 16  wherein the composition is administered to a animal subcutaneously.  
     
     
         18 . A composition for treatment of the symptoms of canine distemper comprising an attenuated canine measles virus at a sub-vaccine level effective to alleviate symptoms of canine distemper in a pharmaceutically acceptable carrier.  
     
     
         19 . The composition of  claim 18  wherein from about 10 −3  TCID 50  to about 500 TCID 50  attenuated canine measles virus per dose.  
     
     
         20 . The composition of  claim 19  which comprises 2 TCID 50  attenuated canine measles virus per dose.

Join the waitlist — get patent alerts

Track US2002123041A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.